Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg
Drug Approval

Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg

This product has sales of about US$ 20 million in Europe

  • By IPP Bureau | January 20, 2024

Shilpa Medicare Limited has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure.

Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. Specifically, Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease.

This product has sales of about US$ 20 million in Europe. As on date, there is one other approved generic in the market.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International